Company: DGLY
Filing Date: 2025-11-12
Form Type: 10-Q
Source: 0001493152-25-021680
Chunk: 266

Company: DIGITAL ALLY, INC.
Filing Date: 2025-11-12
Form: 10-Q
Item: Part I, Item 2
Chunk 266
---
 of law enforcement agencies, including the timing, amount and restrictions on such funding; (6) our ability
to maintain or expand our share of the market for our products in the domestic and international markets in which we compete, including
increasing our international revenues; (7) our ability to produce our products in a cost-effective manner; (8) competition from larger,
more established companies with far greater economic and human resources; (9) our ability to attract and retain quality employees; (10)
risks related to dealing with governmental entities as customers; (11) our expenditure of significant resources in anticipation of sales
due to our lengthy sales cycle and the potential to receive no revenue in return; (12) characterization of our market by new products
and rapid technological change; (13) our dependence on sales of our EVO-HD, DVM-800, DVM-250 and FirstVU products; (14) that stockholders
may lose all or part of their investment if we are unable to compete in our markets and return to profitability; (15) defects in our
products that could impair our ability to sell our products or could result in litigation and other significant costs; (16) our dependence
on a few manufacturers and suppliers for components of our products and our dependence on domestic and foreign manufacturers for certain
of our products; (17) our ability to protect technology through patents and to protect our proprietary technology and information, such
as trade secrets, through other similar means; (18) our ability to generate more recurring cloud and service revenues; (19) risks related
to our license arrangements; (20) the fluctuation of our operation results from quarter to quarter; (21) sufficient voting power by coalitions
of a few of our larger stockholders, including directors and officers, to make corporate governance decisions that could have a significant
effect on us and the other stockholders; (22) the issuance or sale of substantial amounts of our Common Stock, or the perception that
such sales may occur in the future, which may have a depressive effect on the market price of our securities; (23) potential dilution
from the issuance of Common Stock underlying outstanding options and warrants; (24) our additional securities available for issuance,
which, if issued, could adversely affect the rights of the holders of our Common Stock; (25) the volatility of our stock price due to
a number of factors, including, but not limited to, a relatively limited public float; (26) our ability